

November 9, 2023

The Manager – Listing Compliance National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400 051.

Dear Madam/ Sir,

Sub: Application for in-principle approval to Scheme of Arrangement amongst Strides Pharma Science Limited and Steriscience Specialties Private Limited and Stelis Biopharma Limited and their respective shareholders ('Draft Scheme') pursuant to Section 230 to 232 read with other applicable provisions of the Companies Act, 2013.

Ref: SEBI Master Circular no. SEBI/ HO/ CFD/ POD-2/ P/ CIR/ 2023/ 93 dated June 20, 2023 (SEBI Circular)

This has reference to the captioned application filed by the Company on September 28, 2023, and subsequently hosting of the Draft Scheme related documents on NSE Website on October 16, 2023.

In terms of the SEBI Circular, Company is required to submit a Complaints Report on the Draft Scheme within 7 days of expiry of 21 days from the date of the hosting of the Scheme on website of NSE.

Accordingly, please find enclosed the Complaints Report for the period from October 16, 2023, upto November 6, 2023.

As detailed in the annexed Complaints Report, the Company has received NIL complaints/ comments from the shareholders on the draft Scheme.

You are requested to kindly take the same on record.

Thanks & Regards, For Strides Pharma Science Limited

Manjula Ramamurthy Company Secretary

ICSI Membership No: A30515

Encl. as above





Complaints Report

Part A

#	Particular	Number	
1	Number of complaints received directly	NIL	
2	Number of complaints forwarded by Stock Exchanges/ SEBI		
3	Total Number of complaints/comments received (1+2)	NIL	
4	Number of complaints resolved	Not Applicable	
5	Number of complaints pending	Not Applicable	

Part B

#	Name of complainant	Date of compliant	Status (Resolved/ Pending)		
NOT APPLICABLE					

For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary

ICSI Membership No: A30515

